The weekly litigation news digest is live. Subscribe now

IP Verse

Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic Cancer - EP3266456

The patent EP3266456 was granted to Ipsen Biopharm on May 5, 2021. The application was filed on Jun 12, 2013 under application number EP17169098A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3266456

IPSEN BIOPHARM
Application Number
EP17169098A
Filing Date
Jun 12, 2013
Status
Granted And Under Opposition
Apr 3, 2021
Publication Date
May 5, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
GENERICS UKFeb 4, 2022ELKINGTON AND FIFEADMISSIBLE
TEVA PHARMACEUTICALSFeb 2, 2022D YOUNGADMISSIBLE
SANDOZFeb 1, 2022KRAUS & LEDERER PARTGMBBADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS8147867
EXAMINATIONWO2012146610
EXAMINATIONWO2013138371
OPPOSITIONEP2861210
OPPOSITIONWO2012146610
OPPOSITIONWO2013138371
SEARCHWO2012146610
SEARCHWO2013138371

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents